TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03337100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Co-Dispensing
Description: Implementation of a naloxone co-dispensing pharmacy program.~The intent of this program is to provide patients prescribed chronic opioid therapy naloxone under the terms of a standing order for potential opioid overdose reversal. Prior to implementing the program, a naloxone standing order will be implemented and pharmacy operational staff will provide training to pharmacy staff about the standing order and a naloxone co-dispensing protocol. Under a co-dispensing protocol, pharmacy staff members will identify opioid prescriptions meeting criteria for co-dispensing, prepare naloxone fills, offer patients naloxone, and provide counseling on its use.
Study: NCT01807897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: Nocturnal continuous positive airway pressure, titrated to minimize apnea-hypopnea index

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nocturnal supplemental oxygen
Description: Nocturnal supplemental oxygen, titrated to 2-4 liters/minute with target of eliminating nocturnal hypoxemia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle and Sleep Education
Description: A 60-minute educational intervention with slide show and printed materials, educating the patient in healthy sleep habits and heart-healthy lifestyle
Study: NCT04243733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CEM and MTA
Description: Pulpotomy agent

Intervention type: OTHER
Group type: OTHER
Intervention: CEM and MTA
Description: Pulpotomy agent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MTA and CEM
Description: Pulpotomy agent

Intervention type: OTHER
Group type: OTHER
Intervention: MTA and CEM
Description: Pulpotomy agent
Study: NCT03989401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimedia video health education
Description: The experimental group conducted multimedia video education while admission.
Study: NCT01807897

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy Lifestyle and Sleep Education
Description: A 60-minute educational intervention with slide show and printed materials, educating the patient in healthy sleep habits and heart-healthy lifestyle

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle and Sleep Education
Description: A 60-minute educational intervention with slide show and printed materials, educating the patient in healthy sleep habits and heart-healthy lifestyle
Study: NCT02624427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of intraocular pressure (IOP)
Description: Measurement of IOP with the following devices: (1) Goldmann tonometer, (2) Dynamic Contour tonometer, and (3) Corvis ST tonometer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of intraocular pressure (IOP)
Description: Measurement of IOP with the following devices: (1) Goldmann tonometer, (2) Dynamic Contour tonometer, and (3) Corvis ST tonometer
Study: NCT04544579

Intervention type: DEVICE
Intervention: Stent grafts anchored in different areas
Description: Endovascular repair of ascending aortic dissection patients with stent grafts anchored in different areas
Study: NCT03893162

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic
Description: The intervention in this study is a multi-strain probiotic which contains:~Bacillus subtilis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus delbrueckii ssp. bulgaricus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus helveticus, Lactobacillus salivarius, Lactococcus lactis ssp. lactis, Streptococcus thermophilus.~Each capsule contains minimum 2 billion live microorganisms per capsule, equivalent to 10 billion live microorganisms per gram.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visually identical capsules in identical packaging containing no active bacteria.
Study: NCT01054001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil 100mg
Description: sildenafil 100mg per oral twice a week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil 100mg
Description: sildenafil 100mg per oral twice a week
Study: NCT02846649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PIER
Description: Daily text message queries with tailored support
Study: NCT00924508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hydrogel patch
Description: occlusion of eczema with a hydrogel patch composed of an adhesive, thin, flexible, hydrogel layer on an impermeable urethane surface.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone (TAC) 0.1% cream
Description: Triamcinolone Acetonide (triamcinolone acetonide cream) is a topical corticosteroid used as anti-inflammatory and antipruritic agent. Each gram of TAC Cream USP, 0.1% contains 1 mg Triamcinolone Acetonide (triamcinolone acetonide cream) in a cream base consisting of cetyl alcohol, glyceryl monostearate, cetyl esters wax, isopropyl palmitate, polysorbate-60, polysorbate-80, propylene glycol and purified water.
Study: NCT03654885

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XEN-45 Gel Stent
Description: XEN-45 gel stent device implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Description: Trabeculectomy surgery
Study: NCT03989362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vopratelimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vopratelimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vopratelimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vopratelimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vopratelimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vopratelimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vopratelimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vopratelimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study: NCT02289872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TruView PCD Video laryngoscope
Description: Video-Laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TruView PCD Video laryngoscope
Description: Video-Laryngoscopy
Study: NCT03989362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study: NCT01106508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEQ506
Study: NCT04508153

Intervention type: DEVICE
Group type: OTHER
Intervention: Leva Pelvic Digital Health System
Description: Pelvic floor muscle training using the pelvic digital health system to treat pelvic floor disorders, specifically stress urinary incontinence.

Intervention type: OTHER
Group type: OTHER
Intervention: Kegel exercises
Description: Pelvic floor muscle training (PFMT), commonly referred to as Kegel exercises, is a first line conservative treatment for pelvic floor disorders, specifically stress urinary incontinence (SUI) or stress-predominant mixed urinary incontinence (SMUI).
Study: NCT02227394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z7200
Description: Total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01).~At visit 2 or 3 (cross-over design)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z7200
Description: Total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01).~At visit 2 or 3 (cross-over design)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort® Turbohaler®
Description: Total dose budesonide/formoterol is 320 mcg/9 mcg. At visit 2 or 3 (cross-over design)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort® Turbohaler®
Description: Total dose budesonide/formoterol is 320 mcg/9 mcg. At visit 2 or 3 (cross-over design)
Study: NCT04558359

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: These patients will receive standard of care treatment. Plasma renin levels and biomarkers of renal function will be measured.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: These patients will receive angiotensin II in addition to standard of care treatment. Plasma renin levels and biomarkers of renal function will be measured.
Study: NCT03291990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 5 fraction hypofractionated stereotactic radiosurgery along with standard temozolomide
Study: NCT00707954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-7284
Description: Patients will receive single ascending dose of TA-7284 in each step (4 doses planned: 25, 100, 200 and 400 mg), once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of TA-7284
Description: Patients will receive placebo tablets in each step, once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
Study: NCT04159792

Intervention type: OTHER
Intervention: no intervention
Description: No intervention
Study: NCT03137498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine 1.5mg/kg IVPB in 50ml normal saline over 10 minutes x 1dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Ketorolac 30mg (1ml) intravenous push injection x 1dose
Study: NCT03086902

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation Catheter
Description: Ablation of PVC with RF energy
Study: NCT03244111

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: simple memory tool
Description: The goals may be implemented using the simple memory tool. Simple memory tool involves using materials such as checklists or diaries to assist with memory.
Study: NCT03086902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo Ablation catheter
Description: Ablation pf PVC with Cryo enerygy
Study: NCT03502902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC 68498
Description: HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.
Study: NCT00367952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apricitabine
Description: 800mg apricitabine twice daily orally for 96 weeks
Study: NCT01087086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crononutrition
Description: After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period (autonomy phase) in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: American Heart Association
Description: After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period (autonomy phase) in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support.
Study: NCT03502902

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03603106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277
Description: Part I: P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: P03277 was administered intravenously with a flow rate of 2 mL/s.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277
Description: Part I: P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: P03277 was administered intravenously with a flow rate of 2 mL/s.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Part I: Placebo was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: Placebo was administered intravenously with a flow rate of 2 mL/s.
Study: NCT04183608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Patients will all receive Adalimumab 160/80/40mg EOW until V1 (W14) followed by 40mg EOW until V2 (W26)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Patients will all receive Adalimumab 160/80/40mg EOW until V1 (W14) followed by 40mg EOW until V2 (W26)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Calprotectin
Description: Fecal calprotectin dosing at home with IBDoc

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: e-Monitoring
Description: e-Monitoring at Week 6, Week 10, Week 14, Week 18, Week 22, Week 26, Week 34, Week 38, Week 42 and Week 48~The patient must complete the first 2 questions of the Mayo score:~* Stool frequency~* The frequency of bleeding~He must also complete the information on his injections

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapy Education
Description: Patient Education at W0, W2, W14, W26 and W38.
Study: NCT02237638

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hVEGF26-104/RFASE
Description: Three intramuscular injections on days 0, 14 and 28, followed by an observational period of 6 weeks. If hererafter VEGF is not (or no longer) neutralized in serum and there is no sign of disease progression, another booster vaccination can be given. This booster can be repeated until disease progression, death or withdrawal from the study.
Study: NCT05265897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAQ
Description: Informational document
Study: NCT02403401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (BAY98-7196)
Description: Levonorgestrel 40 µg/d intravaginal ring (treatment for 365 days, 28 days wearing period for each ring)
Study: NCT02489669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA)
Description: Patients in the RenalGuard group will be treated by hydration with normal saline controlled by the RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA). The RenalGuard system includes a) a closed loop fluid management system; b) a high volume fluid pump, c) a high accuracy dual weight measuring system; d) motion detection artifact reduction; e) a single use intravenous set and urine collection system that interfaces with a standard Foley catheter; f) real-time display of urine and replacement fluid volume; g) a timely alerts to drain the urine bag or to replace the hydration fluid bag; f) and safety features such as automatic air and occlusion detection.
Study: NCT02599753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-FDTBZ
Description: During this study, participants will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~The proposed dose for this study is based on the investigators' phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010).
Study: NCT04650477

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fixation while forearm in extension-pronation position
Description: Fixation was performed after tenodesis in the extension-pronation position, which is the anatomically most suitable position of the biceps tendon.
Study: NCT03904407

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus Probiotic Capsule
Description: One over-the-counter, probiotic capsule taken by mouth once daily for 4 weeks. Each capsule contains 10 billion cells comprised of:~* Lactobacillus crispatus LbV 88~* Lactobacillus jensenii LbV 116~* Lactobacillus gasseri LbV 150N~* Lactobacillus rhamnosus LbV 96
Study: NCT00901199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO)
Description: All subjects will be given Deferasirox 20-30 mg/kg for 7 days per week. All subject will be given Deferoxamine 50 mg/kg for 3-7 days per week. The number of days for Deferoxamine will be determined by liver iron concentration at baseline.
Study: NCT04766008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Diabetic patients treated with metformin undergoing coronary angiography will not suspend metformin before and after PCI.
Study: NCT03458468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 1g Tranexamic acid prior to skin incision
Study: NCT02353195

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Radiofrequency
Description: The equipment used, 35-mm diameter CAP and 30-mm diameter RES movable electrode was used on the affected site, and a planar electrode was used as a return electrode on the abdomen. The electricity was administered in the following manner: cream was applied to the site with the severest pain and its adjacent area, and the electrical output was increased by moving the movable electrode within the patient´s tolerance level, while monitoring the skin temperature tolerable to the patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: The equipment used, 35-mm diameter CAP and 30-mm diameter RES movable electrode was used on the affected site, and a planar electrode was used as a return electrode on the abdomen. The electricity was administered in the following manner: cream was applied to the site with the severest pain and its adjacent area, and the electrical output was increased by moving the movable electrode within the patient´s tolerance level, while monitoring the skin temperature tolerable to the patient.
Study: NCT05977829

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Transvaginal ultrasound to carry out uterine surveillance

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Transvaginal ultrasound to carry out uterine surveillance

Intervention type: DIAGNOSTIC_TEST
Intervention: Hysteroscopy
Description: Outpatient hysteroscopy to carry out uterine surveillance

Intervention type: DIAGNOSTIC_TEST
Intervention: Hysteroscopy
Description: Outpatient hysteroscopy to carry out uterine surveillance
Study: NCT03719989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine plus R-GDP
Description: azacitidine S.C 25 mg/m2 D1,2,3,4,5 rituximab I.V. 375 mg/m2 D8 gemcitabine I.V. 1,000 mg/m2, D8,15 dexamethasone I.V. or P.O. 40 mg D8,9,10,11 every 21 days, up to 6 cycles
Study: NCT03122782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical application Tranexamic acid
Description: Tranexamic acid (TXA) will be injected to distinction media during hysteroscopy in myomectomy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Normal saline)
Description: 5ml of normal saline will be added to every 500 ml of distension media
Study: NCT01309776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tianeptine
Description: week1 : 25mg/day q.d., week2: 37.5mg/day b.i.d. (12.5mg 1T, 12.5mg 2T

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: week1 : 5mg/day q.d., week2: 10mg/day q.d.
Study: NCT03408184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar paravertebral group
Description: A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The field block group
Description: A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
Study: NCT01743742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E, Vitamin C